Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant

There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentatio...

Full description

Bibliographic Details
Main Authors: Gaetano Cicchitto, Lorena Cardillo, Claudio de Martinis, Paola Sabatini, Rosita Marchitiello, Giovanna Abate, Adele Rovetti, Antonietta Cavallera, Camillo Apuzzo, Francesco Ferrigno, Giovanna Fusco
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Viruses
Subjects:
SARS-CoV-2
monoclonal antibody treatment
casirivimab/imdevimab
variants of concern
B.1.617.2
delta variant
Online Access:https://www.mdpi.com/1999-4915/14/3/650

Internet

https://www.mdpi.com/1999-4915/14/3/650

Similar Items